A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
Clinical trial NCT05535244 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05535244
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-17
- Primary completion
- 2027-02-26
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.